EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study

Jiayu Wang, Yunjiang Liu, Qingyuan Zhang, Wei Li, Jifeng Feng, Xiaojia Wang, Jianmin Fang, Yiqun Han, Binghe Xu

Cancer Communications · 2024-07 · 44 (7) · 833-851

DOI: 10.1002/cac2.12577 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Communications, online erschienen am 28.06.2024. Verfasst von Jiayu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: RemeGen Co., Ltd, CAMS Innovation Fund for Medical Sciences (CIFMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Disitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast, gastric, and ovarian cancers with different levels of HER2 expression. In this pooled analysis, we report the safety and efficacy of DV in patients with HER2‐overexpression and HER2‐low advanced breast cancer (ABC).

Methods

In the phase I dose‐escalation study (C001 CANCER), HER2‐overexpression ABC patients received DV at doses of 0.5‐2.5 mg/kg once every two weeks (Q2W) until unacceptable toxicity or progressive disease. The dose range, safety, and pharmacokinetics (PK) were determined. The phase Ib dose‐range and expansion study (C003 CANCER) enrolled two cohorts: HER2‐overexpression ABC patients receiving DV at doses of 1.5‐2.5 mg/kg Q2W, with the recommended phase 2 dose (RP2D) determined, and HER2‐low ABC patients receiving DV at doses of 2.0 mg/kg Q2W to explore the efficacy and safety of DV in HER2‐low ABC.

Results

Twenty‐four patients with HER2‐overexpression ABC in C001 CANCER, 46 patients with HER2‐overexpression ABC and 66 patients with HER2‐low ABC in C003 CANCER were enrolled. At 2.0 mg/kg RP2D Q2W, the confirmed objective response rates were 42.9% (9/21; 95% confidence interval [CI]: 21.8%‐66.0%) and 33.3% (22/66; 95% CI: 22.2%‐46.0%), with median progression‐free survival (PFS) of 5.7 months (95% CI: 5.3‐8.4 months) and 5.1 months (95% CI: 4.1‐6.6 months) for HER2‐overexpression and HER2‐low ABC, respectively. Common (≥5%) grade 3 or higher treatment‐emergent adverse events included neutrophil count decreased (17.6%), gamma‐glutamyl transferase increased (13.2%), asthenia (11.0%), white blood cell count decreased (9.6%), peripheral neuropathy such as hypoesthesia (5.9%) and neurotoxicity (0.7%), and pain (5.9%).

Conclusion

DV demonstrated promising efficacy in HER2‐overexpression and HER2‐low ABC, with a favorable safety profile at 2.0 mg/kg Q2W.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsImmunoconjugatesHumansFemaleMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

HER2‐lowHER2‐overexpressionantibody‐drug conjugatebreast cancerclinical trialsdisitamab vedotin

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
  • Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
  • Department of Breast Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
  • Department of Medical Oncology, The First Hospital of Jilin University, Changchun, Jilin, P. R. China.
  • Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China.
  • Department of Breast Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.

Förderung

  • RemeGen Co., Ltd
  • CAMS Innovation Fund for Medical Sciences (CIFMS)

Zitieren

APA

Wang, J., Liu, Y., Zhang, Q., Li, W., Feng, J., Wang, X., Fang, J., Han, Y., & Xu, B. (2024). Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study. Cancer Communications, 44(7), 833-851. https://doi.org/10.1002/cac2.12577

Vancouver

Wang J, Liu Y, Zhang Q, Li W, Feng J, Wang X, et al. Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study. Cancer Communications. 2024;44(7):833-851. doi:10.1002/cac2.12577

BibTeX
@article{Wang2024,
  author = {Wang, Jiayu and Liu, Yunjiang and Zhang, Qingyuan and Li, Wei and Feng, Jifeng and Wang, Xiaojia and Fang, Jianmin and Han, Yiqun and Xu, Binghe},
  title = {Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study},
  journal = {Cancer Communications},
  year = {2024},
  volume = {44},
  number = {7},
  pages = {833--851},
  doi = {10.1002/cac2.12577}
}
Kostenlos starten →